LensAR, Inc.
76 articles about LensAR, Inc.
-
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
3/4/2024
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives.
-
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
3/1/2024
LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock.
-
LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
2/26/2024
LENSAR, Inc. today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024.
-
LENSAR Reports Third Quarter 2023 Results and Provides Business Update
11/9/2023
LENSAR, Inc. announced financial results for the quarter ended September 30, 2023 and provided an update on key operational initiatives.
-
LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
11/2/2023
LENSAR, Inc. today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023.
-
LENSAR Reports Second Quarter 2023 Results and Provides Business Update
8/9/2023
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2023 and provided an update on key operational initiatives.
-
LENSAR to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
8/2/2023
LENSAR, Inc. today announced that the Company’s second quarter 2023 financial results will be released before market open on Wednesday, August 9, 2023.
-
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
7/24/2023
LENSAR, Inc. announced that it has completed the installation of multiple ALLY Systems in five private equity-owned ophthalmology groups, including EyeSouth Partners’ network.
-
LENSAR Reports First Quarter 2023 Results and Provides Business Update
5/15/2023
LENSAR, Inc. today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational initiatives.
-
LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023
5/10/2023
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2023 financial results will be released before market open on Monday, May 15, 2023.
-
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
3/16/2023
LENSAR, Inc. today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives.
-
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
3/9/2023
LENSAR, Inc. today announced that the Company’s fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023.
-
LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results
2/14/2023
LENSAR, Inc. announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of its ALLY® Adaptive Cataract Treatment System.
-
LENSAR to Present at Two Upcoming Investor Conferences - November 22, 2022
11/22/2022
LENSAR, Inc. today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences.
-
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
11/9/2022
LENSAR, Inc. today announced financial results for the quarter ended September 30, 2022 and provided a business update.
-
LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022
11/2/2022
LENSAR, Inc. today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022.
-
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU
9/8/2022
LENSAR, Inc. announced the application for certification of the ALLY™ Adaptive Cataract Treatment System in the European Union.
-
First Patients Treated with LENSAR’s® ALLY™ Adaptive Cataract Treatment System
8/16/2022
First Patients Treated with LENSAR’s ® ALLY ™ Adaptive Cataract Treatment System.
-
LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update
8/8/2022
LENSAR, Inc. today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.
-
LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
8/1/2022
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial results will be released before market open on Monday, August 8, 2022.